Results 21 to 30 of about 166,832 (321)

Use of warfarin in long-term care: a systematic review

BMC Geriatrics, 2012
Background The use of warfarin in older patients requires special consideration because of concerns with comorbidities, interacting medications, and the risk of bleeding.
Neidecker Marjorie, Patel Aarti A, Nelson Winnie W, Reardon Gregory   +3 more
doaj   +1 more source

Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry

Pharmaceutics, 2022
Warfarin is extensively used for venous thromboembolism and other coagulopathies. In clinical settings, warfarin is administered as a mixture of S- and R-warfarin, and both enantiomers are metabolized by multiple cytochrome P450 enzymes into many ...
Shasha Jin, Zhihong Li, Qing Yang, Boyu Fang, Xiaoqiang Xiang, Chao Peng, Weimin Cai   +6 more
doaj   +1 more source

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand, Förch, Christian, Lindhoff-Last, Edelgard, Mirceska, Ana, Pfeilschifter, Josef Martin (Prof. Dr.), Pfeilschifter, Waltraud, Steinmetz, Helmuth   +6 more
core   +10 more sources

Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]

, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ, Farag, Mohamed, Gorog, Diana, Gue, Ying X., Lip, Gregory Y H, Spinthakis, Nikolaos, Srinivasan, Manivannan, Wellsted, David   +7 more
core   +3 more sources

Standardized warfarin monitoring decreases adverse drug reactions

BMC Family Practice, 2019
Background While warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern.
Lisa B. E. Shields, Paula Fowler, Diane M. Siemens, Douglas J. Lorenz, Kenneth C. Wilson, Steven T. Hester, Joshua T. Honaker   +6 more
doaj   +1 more source

Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery

Research in Cardiovascular Medicine, 2015
Background: Warfarin is an anticoagulant and is widely used for the prevention of thromboembolic events. Genetic variants of the enzymes that metabolize warfarin, i.e.
Avisa Tabib, Babak Najibi, Mohammad Dalili, Ramin Baghaei, Behzad Poopak   +4 more
doaj   +1 more source

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

An Atypical Case of Warfarin-Induced Skin Necrosis

Clinical Practice and Cases in Emergency Medicine, 2017
Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients.
Lindsay R. Sklar, Anne Messman
doaj   +1 more source

Bleeding Incidence in Patients Administered with Warfarin at Secondary Hospitals in Yogyakarta Province

Indonesian Journal of Pharmacy, 2020
Warfarin is an oral anticoagulant most-commonly prescribed for prevention and treatment of thromboembolism. It is widely acknowledged that warfarin has both narrow therapeutic index and various drug-food interactions, thus carrying the risk of ...
Vitarani D.A Ningrum, Sufiyah Sufiyah, Irine Dyah Widyastuti, Bacrie Sufriyanto Yusuf, Wahyudin Dullah   +4 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source